[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats]

Hui Jiang1, Rui-jin Guan, Hong-yan Wang

  • 1Provincial Clinic College, Fujian Medical University, Cardiovascular Disease Institute, Fujian Provincial Hospital, Fuzhou 350001, China.

Abstract

Insights

Fasudil effectively reverses monocrotaline-induced pulmonary arterial hypertension (PAH) in rats by reducing ROCK-1 and MYPT-1 expression. This treatment improved survival rates and key hemodynamic parameters in PAH models.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Pulmonary Medicine

Background:

  • Pulmonary arterial hypertension (PAH) is a severe condition characterized by high blood pressure in the pulmonary arteries.
  • Monocrotaline (MCT) is a toxin commonly used to induce experimental PAH in animal models.
  • Rho-kinase (ROCK) signaling pathways are implicated in the pathogenesis of PAH.

Purpose of the Study:

  • To investigate the therapeutic effects of fasudil on monocrotaline-induced pulmonary arterial hypertension (PAH) in a rat model.
  • To elucidate the underlying mechanisms, specifically the role of ROCK-1 and MYPT-1, in fasudil's action on PAH.

Main Methods:

  • Rats were induced with monocrotaline (MCT) to develop PAH.
  • Fasudil hydrochloride was administered to a subset of PAH rats during the established disease phase.
  • Hemodynamic parameters (RVSP, mPAP), right ventricular hypertrophy, pulmonary artery wall remodeling, and ROCK-1/MYPT-1 expression (mRNA and protein) were assessed.

Main Results:

  • Fasudil treatment significantly improved survival rates in MCT-induced PAH rats compared to untreated controls.
  • Fasudil administration markedly reduced right ventricular systolic pressure, mean pulmonary artery pressure, and right ventricular hypertrophy.
  • Fasudil downregulated the expression of ROCK-1 mRNA and protein, as well as MYPT-1 protein and its phosphorylation in lung tissue.

Conclusions:

  • Fasudil demonstrates significant efficacy in reversing established monocrotaline-induced pulmonary arterial hypertension in rats.
  • The therapeutic effects of fasudil are associated with the downregulation of the ROCK-1 and MYPT-1 signaling pathway.
  • Fasudil represents a potential therapeutic agent for PAH, targeting key molecular mechanisms involved in vascular remodeling and vasoconstriction.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...